pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Tybost
drug
save

cobicistat

Marketedupdated 3mo ago
by $GILD GILEAD SCIENCES, INC.
Approved
community read0 votes

🐶 often sniffed alongside

top 5
  • tagApproval38 co-mentions · 19 sources
  • drug(cobicistat + darunavir)19 co-mentions · 19 sources
  • drug(cobicistat + darunavir) ODT19 co-mentions · 19 sources
  • tagSmall Molecule19 co-mentions · 19 sources
  • drugdarunavir1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

Trials studying cobicistat

  • phase4A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatmentsrecruitingn=350
  • phase3Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVactive not recruitingn=133
  • phase1A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.completedn=28
  • phase2A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutationrecruitingn=447
  • —Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartumcompletedn=205
  • phase2ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancercompletedn=175
  • phase4A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participantscompletedn=8
  • phase1Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participantscompletedn=30
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Aug 22, 2026
2 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

  • Apr 6, 2033patentUS 10039718*PED
  • Apr 6, 2033patentUS 10039718*PED
  • Oct 6, 2032formulationUS 10039718
  • Oct 6, 2032formulationUS 10039718
  • Mar 3, 2030patentUS 8148374*PED3.5y
  • Mar 3, 2030patentUS 8148374*PED3.5y
  • Sep 3, 2029compositionUS 81483743.0y
  • Sep 3, 2029compositionUS 81483743.0y

FDA exclusivities (1)

  • Aug 22, 2026ODE-260Orphan Drug (7y)2d

News(0)

no news has mentioned this drug yet

brand
Tybost
generic
cobicistat
indication
Human Immunodeficiency Virus (HIV) Infections (AIDS)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 19m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?